Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
- PMID: 35700443
- PMCID: PMC9788807
- DOI: 10.1093/rheumatology/keac326
Correction to: Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus
Erratum for
-
Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus.Rheumatology (Oxford). 2021 Nov 3;60(11):5397-5407. doi: 10.1093/rheumatology/keab381. Rheumatology (Oxford). 2021. PMID: 33956056 Free PMC article. Clinical Trial.
